




DEC 19, 2022

IN DEVELOPMENT

Diagnostic value of PD-L1  $\geq$  1% expression status and its efficacy correlation with PD-1/PD-L1 inhibitor therapy in advanced solid cancers: a meta-analysis

DOI

[dx.doi.org/10.17504/protocols.io.8epv5j2p5l1b/v1](https://dx.doi.org/10.17504/protocols.io.8epv5j2p5l1b/v1)Anonymous<sup>1</sup><sup>1</sup>Fuzhou First Hospital

Anonymous

COMMENTS 0

## DISCLAIMER

## DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to [protocols.io](https://protocols.io) is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with [protocols.io](https://protocols.io), can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

## ABSTRACT

Despite immune checkpoint inhibitors (ICIs) seem to have found their role in several hematological and solid tumors, several questions remain unanswered. Among these, the lack of validated biomarkers of response represents an important issue since only a proportion of patients benefit from immunotherapy. Based on these premises, a greater understanding of the role of potential biomarkers including programmed death ligand 1 (PD-L1) expression, tumor mutational burden (TMB), microsatellite instability (MSI) status, gut microbiota and several others is fundamental. In addition, clinical trials on immunotherapy widely differed in terms of drugs, patients, designs, terms of study phases, and inconsistent clinical outcomes.

## ATTACHMENTS

[1215 Protocol.docx](#)

DOI

[dx.doi.org/10.17504/protocols.io.8epv5j2p5l1b/v1](https://dx.doi.org/10.17504/protocols.io.8epv5j2p5l1b/v1)

## PROTOCOL CITATION

Anonymous 2022. Diagnostic value of PD-L1  $\geq$  1% expression status and its efficacy correlation with PD-1/PD-L1 inhibitor therapy in advanced solid cancers: a meta-analysis.  
**protocols.io**  
<https://dx.doi.org/10.17504/protocols.io.8epv5j2p5l1b/v1>



## FUNDERS ACKNOWLEDGEMENT

xiaoyan zhou

## LICENSE

\_\_\_\_\_ This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

## CREATED

Dec 18, 2022

## LAST MODIFIED

Dec 19, 2022

## PROTOCOL INTEGER ID

74177